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Abstract
Objectives: To study the incidence of, and risk factors for, iatrogenic hypoglycaemia following 
GwI infusion in our institution.
Context: Hyperkalaemia is a life-threatening biochemical abnormality. Glucose-with-insulin (GwI) 
infusions form standard management, but risk iatrogenic hypoglycaemia (glucose ≤ 3.9mmol/L). 
Recently updated UK guidelines include an additional glucose infusion in patients with pre-
treatment capillary blood glucose (CBG) <7.0 mmol/L. 
Design: Retrospective analysis of outcomes for GwI infusions prescribed for hyperkalaemia from 
1st January-28th February 2019, extracted from the Newcastle-upon-Tyne Hospitals NHS 
Foundation Trust electronic platform (eRecord).
Participants: 132 patients received 228 GwI infusions for hyperkalaemia.
Main outcome measures: Incidence, severity and time-to-onset of hypoglycaemia.
Results: Hypoglycaemia incidence was 11.8%. At least 1 hypoglycaemic episode occurred in 
18.2% of patients with 6.8% having at least 1 episode of severe hypoglycaemia (<3.0 mmol/L). 
Most episodes (77.8%) occurred within 3 hours of treatment.
Lower pre-treatment CBG(5.9 mmol/L  [4.1 mmol/L - 11.2 mmol/L],; versus 7.6 mmol/L  [3.7 
mmol/L - 31.3 mmol/L], p = 0.000) was associated with hypoglycaemia risk. A diagnosis of type 2 
diabetes and treatment for hyperkalaemia within the previous 24 hours were negatively 
associated.
Conclusions: Within our inpatient population, around 1 in 8 GwI infusions delivered as treatment 
for hyperkalaemia resulted in iatrogenic hypoglycaemia. Higher pre-treatment CBG and a 
diagnosis of type 2 diabetes were protective, irrespective of renal function. Our findings support 
the immediate change to current management, either with additional glucose infusions, or by 
using glucose-only infusions in patients without diabetes. These approaches should be compared 
via a prospective randomised study.
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Introduction
Hyperkalaemia is a commonly encountered but potentially life-threatening biochemical 
abnormality, with a reported incidence of between 1-10% in hospital inpatients, particularly 
among those with renal impairment 1,2. Due to the effects of potassium on cardiac myocyte 
resting membrane potential, hyperkalaemia is associated with a significant risk of developing 
arrhythmias and cardiac arrest, and  potassium (K+) levels ≥ 6.5 mmol/L (normal range 3.5-5.3 
mmol/L) warrant urgent treatment 3. There is surprisingly limited evidence behind the current 
guidelines for treating hyperkalaemia in hospital inpatients, and there is wide variation in clinical 
practice both within and between individual centres.
Glucose-with-insulin (GwI) infusions form part of the current UK national guidelines from 
the Renal Association for treatment of hyperkalaemia4, based on the physiological observation 
that insulin stimulates the activity of the Na+-K+ ATP pump, which leads to an influx of potassium 
into cells and a corresponding reduction in extracellular fluid potassium.
Previous publications have highlighted the risk of iatrogenic hypoglycaemia (capillary 
blood glucose ≤ 3.9mmol/L) following hyperkalaemia treatment with GwI infusions; the reported 
incidence ranging from 6% to 75%5-9. Patients with hyperkalaemia may have additional risk 
factors for hypoglycaemia, such as end-stage renal disease, or diabetes treated with insulin or 
insulin secretagogue therapy. Hypoglycaemia has potentially life-threatening consequences, 
including precipitation of acute cardiovascular events and cardiac arrhythmia, and may cause life-
changing generalised brain injury in the long term. Hypoglycaemia among hospitalised inpatients 
has also been linked to increased morbidity, mortality and length-of-stay 10. 
Consideration of the above evidence has led to some changes in the updated UK Renal 
Association (UKRA) guidelines (July 202011), which now recommend:
1. Treat all patients requiring GwIwith 10 units of soluble insulin and 25g dextrose
2. In addition, give 10% dextrose at a rate of 50ml/hr for 5 hrs in patients with pre 
treatment glucose < 7 mmol/L
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Our aim was to determine the incidence of iatrogenic hypoglycaemia following GwI 
infusions in our inpatient population, as well as to determine any predictive factors for 
development of hypoglycaemia. 
Methods
We performed a retrospective audit within the Newcastle-upon-Tyne Hospitals NHS Foundation 
Trust to determine the incidence of iatrogenic hypoglycaemia in adult patients receiving GwI 
infusions for the treatment of hyperkalaemia. Caldicott approval was granted for data access and 
the project was registered with the trust Audit registry (Clinical Governance & Audit Registration 
No.9889). Data on all patients prescribedGwI infusions as treatment for hyperkalaemia from 
1stJanuary to 28thFebruary 2019 was extracted from the trust electronic prescribing system 
“eRecord”. 
Our trust guidelines recommend treatment with GwI infusion for all patients with 
potassium level ≥ 6.5 mmol/L, or potassium 6-6.4 mmol/L with ECG changes, or where there are 
other reasons for concern. GwI as per trust protocol contains 10 units of Actrapid ® (short acting 
human insulin), infused over 15 minutes, in either 50 ml of 50% dextrose (i.e. 25g glucose), or 
100ml of 20% dextrose (20g glucose) in patients where there are concerns about the reliability of 
IV access. Capillary blood glucose (CBG) is recorded at baseline, and at 15 minutes, 30minutes, 
60 minutes, 90 minutes, 2 hours, 3 hours, 4 hours and 6 hours from the onset of the infusion. All 
patients who developed hypoglycaemia (defined as CBG ≤ 3.9mmol/L) up to six hours following 
GwI infusions were included in the “hypoglycaemia” cohort, and werecompared against those 
who did not develop hypoglycaemia. 
The following data were extracted from eRecord: age and sex of patient, date and time of 
infusion, baseline capillary glucose, pre- and post-treatment potassium level and renal function at 
the time of treatment. Body mass index (BMI) was not available for the majority of patients, as 
patient weight and height is not reliably recorded during acute admissions within our 
trust.Previous diagnoses of diabetes (including treatment modality), chronic kidney disease (CKD; 
defined as a persistent estimated glomerular filtration rate – eGFR of <60ml/min/1.73m2 in the 3 
to 6 months preceding admission) and chronic liver disease were also recorded.The reduction in 
potassium after treatment was determined from the nadir potassium level within six hours of 
infusion. Hypoglycaemia was defined as capillary blood glucose <4.0mmol/L, and severe 
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Inpatient Audit definitions12. The data that support the findings of this study are available from the 
corresponding author upon reasonable request. 
Results were analysed using IBM® SPSS Statistics® (Version 26, Chicago, IL). In univariate 
analysis for the key outcome of development of hypoglycaemia, continuous variables of interest 
were compared with independent-samples t-test or Mann-Whitney U test depending on their 
distribution. The categorical variables were analysed with Chi-Square statistic or Fisher’s exact 
test. Analysis of time to hypoglycaemia against renal function was by Kruskal-Wallis test for 
categorical data (existing CKD diagnosis) or by Pearson correlationfor continuous data (serum 
creatinine).Results are presented using median and range for continuous variables unless stated 
otherwise, and with odds ratios with 95% confidence intervals (CI) for categorical variables.
Results 
Baseline Demographics
Data was extracted for 132 patients (86 males and 46 females). The median age of participants 
was 67 years (range: 19-95 years). There was no significant difference in age between males 
(median: 66 years [range: 23-95 years]) and females (median: 72 years [range: 19-95 years], 
(Mann-Whitney U, p = 0.481). A total of 261 GwI infusions were prescribed for these patients 
between 01/01/2019 and 28/02/2019for treatment of hyperkalaemia. Thirty threeepisodes of GwI 
infusions were excluded from analysis due to lack of recorded baseline blood glucose, post-
treatment potassium or non-standard time points, leaving 228 infusions (prescribed to 132 
patients).
A prior diagnosis of diabetes mellitus was recorded in 37.9% (95% CI: 30.1-46.4%; n = 
50/132). As expected from a cohort experiencing hyperkalaemia, 54.6% (95% CI: 46.1-62.8%; n= 
72/132) had an established diagnosis of CKD G3 or above (on basis of prior eGFR). 
Incidence and severity of hypoglycaemia
At least one episode of hypoglycaemia occurred in 18.2% of patients (95% CI: 12.5%-25.6%; n = 
24/132) with 6.82% (95% CI:3.63%-12.45%; n = 9/132) having at least one episode of severe 
hypoglycaemia (<3.0mmol/L).There were 27(11.8%, 95% CI: 8.3-16.7%) episodesof 
hypoglycaemia within the six hours after treatment recorded among 228 infusions prescribed.
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In univariate analysis, the age (OR 0.987/year, 95% CI: 0.960-1.014, p = 0.345) and sex (OR 
2.325, males versus females; 95% CI: 0.806-6.705, p = 0.118) of the patient were not significant 
predictors of having at least one episode of hypoglycaemia following GwItreatment. 
In wider univariate analysis of patient-level factors,a prior diagnosis of type 2 diabetes 
mellitus appeared to be protective against hypoglycaemia (OR 0.079, 95% CI: 0.010-0.616, p = 
0.015). A diagnosis of type 1 diabetes, treatment with insulin or a sulfonylurea and degree of 
chronic kidney disease were not significantly associated with hypoglycaemia(Table 1).No patients 
(0/19) in the hypoglycaemia group had a recorded diagnosis of chronic liver disease, therefore we 
did not pursue further analysis.
Episode-Level Factors
With the data available, we expressed the following epidemiological data by discrete 
hyperkalaemia episode, rather than per patient(Table 2).
The median pre-treatment glucose was significantly lower in those that developed 
iatrogenic hypoglycaemia (5.9 mmol/L [range: 4.1 mmol/L - 11.2 mmol/L], n = 27; versus 7.6 
mmol/L [range: 3.7 mmol/L - 31.3 mmol/L], n = 201; Mann-Whitney U, p = 0.000). There was a 
strong association between higher pre-treatment glucose levels and reduction in hypoglycaemia 
events (OR 0.669/mmol, 95% CI: 0.520-0.860, p = 0.002). Indeed, the 2020 UKRA guidelines 
recommend the use of a <7 mmol/L threshold for pre-infusion glucose as being at increased risk 
of hypoglycaemia11. We support the use of this threshold, identifying a strong relationship (OR 
4.146; 95% CI: 1.676-10.255, p = 0.002) between hypoglycaemia and pre-infusion glucose <7 
mmol/L(Figure 2).
The median number of treatments per patient was 1 (range 1-12),but 34.1% (n = 45/132) 
of patients had more than one treatment episode.The number of treatments across the patient’s 
admission was inversely associated with episodes of hypoglycaemia (OR 0.347, 95% CI: 0.123-
0.975, p = 0.045) following GwI infusion. This may be a marker of insulin resistance in this group.
Whilst there was a slight statistically significant difference between the median pre-
treatment potassium it was not a significant predictor in univariate odds analysis of 
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Of the infusions prescribed, only 4.4% (95% CI: 2.4%-7.9%; n = 10/228) utilised 20% 
dextrose, whilst the majority (95.6%) used 50% dextrose. Due to the small number in the first 
group, and indeed the small difference in administered glucose (20g versus 25g), we have not 
compared these variables separately.
There were no significant differences foundin age, current renal function, or previous 
diagnosis of CKD between those developing hypoglycaemia and those who did not. Similarly, 
there was no difference in potassium response to treatment (Table 2).
Time to developing hypoglycaemia 
Figure 1demonstratesthat most episodes of hypoglycaemia occurred within the first 3 hours of 
receiving GwI infusions, with 51.9% of hypoglycaemia episodes occurring within 2 hours, and 
77.8% within 3hours of the infusion. The median time to development of hypoglycaemia was 110 
minutes (range 35-221 minutes). There were no episodes of hypoglycaemia recorded between 4 
and 6 hours after infusion.There was no effect on time to hypoglycaemia demonstrated in patients 
with existing CKD (H(3) = 0.669; p = 0.880), or depending on serum creatinine at the time of 
treatment (r =-0.09; R2 = 0.008;  p = 0.677).
Discussion
The incidence of iatrogenic hypoglycaemia following GwI infusions for hyperkalaemia within our 
study population was 11.8%, which is similar to the rates (6.1% to 17.5%) reported in other 
studies (Table 3)6-8,13-16. The rate of hypoglycaemia we observed was slightly lower than in 
another recent UK studyby Boughton et al13; however, this is most probably because their 
protocol involved administering 10 units of insulin in a lower (20g) glucose load, whereas 95.6% 
of the infusions in our cohort contained a 25g total glucose load (as recommended inthe 2014 
Renal Association guidelines). Taking into account the number of patients having recurrent 
infusions, 18.2% of patients (95% CI: 12.5%-25.6%; n = 24/132) developed hypoglycaemia after 
receiving GwI infusions for the treatment of hyperkalaemia which, in our view, represents an 
unacceptable level of riskto patients. 
Lower pre-treatment capillary blood glucose was identified as the main risk factor for 
development of hypoglycaemia in ouranalysis. A prior recorded diagnosis of type 2 diabetes 
appeared protective, reflecting insulin resistance in this group.Only one previous study6 has 
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stage renal disease, and therefore generalisability is limited. Our findings show importantly and 
uniquely, that a diagnosis of type 2 diabetes appears protective regardless of pre-existing 
renal function.
Several suggestions have been made to reduce risk of hypoglycaemia from GwI 
infusions9,17, including administering a lower dose of insulin, pre-loading with additional glucose or 
administering a higher overall glucose load. 
It is evident that graded release of endogenous insulin occurs as part of the normal 
physiological response to a glucose load18. Hence for hyperkalaemic patients without a diagnosis 
of diabetes or other disorders of insulin regulation, administering intravenous glucose alone is 
potentially an effective treatment, and eliminates the risk of iatrogenic hypoglycaemia.
A small crossover study by Chothiaet al. in non-diabetic patients with hyperkalaemia 
examined this principle.  After infusion of 50g dextrose, with- or without- 10 units of insulin, they 
did find a mean K+ drop of 0.5 (+/- 0.31) mmol/L with dextrose alone, however this was slightly 
less than the 0.83 (+/- 0.53) mmol/L reduction in the group treated with conventional GwI 
(p=0.01)17. Although this approach is currently not recommended in the latest UKRA guideline 
iteration, we would strongly support further investigation of this approach, with a view to future 
guidelines being multidisciplinary, rather than monospecialty-derived.
We believe there needs to be an immediate change to practice in order to reducethe 
present unacceptable risk of developing hypoglycaemia with GwI infusions for hyperkalaemia, 
particularly in patients with a lower pre-treatment glucose level and without type 2 diabetes. 
However, the question is whether to adopt the proposal in recently updatedUKRA guidelines to 
administer an additional glucose load of 25g, or more simply, to administer glucose-only infusions 
for this patient group. We propose that the safety and efficacy of these two approaches be 
subject to prospective study.In the interim, we propose the following changes (Figure 3) to the 
hyperkalaemia management protocol within our trust and suggest that this can be adopted by 
other institutions, due to concerns regarding patient safety with existing protocols as highlighted 
by our audit.
There were limitations to our analysis. Due to insufficient data, we were unable to perform 
rigorous within-person risk factor analysis for those who underwent multiple GwI treatments. We 
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glucose) basis. Examination of whether repeated GwI infusions increased hypoglycaemia risk 
over a 24-hour time period in fact found the opposite association. This may be another marker of 
insulin resistance in such patients. Similarly, for patients with diabetes, medication,including 
insulin injections, given on the same day could theoretically have contributed to greater risk of 
hypoglycaemia, but we found these patients to have a lower incidence of hypoglycaemia. We did 
not have sufficient data available to assess whether body mass index affected risk of 
hypoglycaemia, as patient weight and height are currently not systematically or reliably recorded 
as part of acute inpatient admissions to our trust.We also did not look at the effect of potential 
concurrent medication (other than insulin or oral hypoglycaemic medication) with hypoglycaemia 
listed as a possible side-effect; however there are likely only small numbers of patients on such 
medication. 
The July 2020UKRA guidelines recommend actively monitoring for hypoglycaemia for 
twelve hours post infusion, which is not our current trust policy. We did not attempt to collect data 
beyond six hours due to potential for introducing bias (e.g. those with a diagnosis of diabetes 
would have had additional blood glucose monitoring). Reassuringly, we did not identify any 
episodes of hypoglycaemia occurring between four and six hours after treatment.
Conclusions
Consistent with previous publications, we determined that around 1 in 8GwI infusions (11.8%) 
delivered as treatment for hyperkalaemia resulted in iatrogenic hypoglycaemia within our inpatient 
population, with 18.2% patients (almost 1 in 5) experiencing this complication.
Having a lower pre-treatment capillary blood glucose level was the main factor associated 
with hypoglycaemia risk, and a prior diagnosis of type 2diabetes may be protective. Our findings 
support UKRA recommendations for giving additional glucose loading for patients with low pre-
treatment glucose level (<7.0mmol/L), but would equally support a robust exploration of using 
glucose-only infusions.  These two approaches should ideally be compared via a prospective 
randomised study, but for the interim, we recommend the immediate revision of current 
approaches to hyperkalaemia treatment for overwhelming reasons of patient safety. 
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Table 1. Predictors of post-treatment hypoglycaemia – Patient Factors
OR -odds ratio; CI – confidence interval; CKD- chronic kidney disease 
Statistical test applied: a Mann Whitney U Test, bChi-Square test
















Median pre-treatment K+ level 
mmol/La(Range)
6.1 (5.2-8) 6.3 (5.4-8.2) 0.024
Median pre-treatment CBG level 
mmol/La(Range)
5.9 (4.1-11.2) 7.6 (3.7-31.3) 0.000
Median creatinine 
mmol/La(Range)
246 (53-684) 170 (50-2114) 0.669
Mean maximal reduction 
in K+ mmol/Lb(+/- SEM)
0.77 +/- 0.09 0.74 +/- 0.05 p = 0.779
Table 2. Predictors of post-treatment hypoglycaemia – Episode-level Factors
CBG – capillary blood glucose; SEM – standard error of the mean
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Apel et al6 2014 Inpatients on 
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Coca et al7 2017 Adult (non 
haemodialysis) 
inpatients (Spain)
(n = 164 episodes)
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Estep et al14 2015 All adult inpatients 
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Table 3. Previous studies investigating iatrogenic hypoglycaemia following GwI infusions
Moderate to Severe Hyperkalaemia 
(K+6.0mmol/L)
Check bedside capillary blood glucose 
& history of diabetes
Capillary blood glucose <7.0mmol/L
OR
No history of diabetes
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OR
Figure 3. Proposed changes to glucose-insulin infusion treatment section in UK Renal Association 
Hyperkalaemia guideline
* optimum dose to be determined by further study
Give 10 units soluble insulin in 25g 
glucose
Give 10 units soluble insulin in 25g 
glucose PLUS
Give 25g glucose load (10% glucose 
@50ml/hr) over 5 hours
Give 75-100g* glucose-only infusion; if 
moderate hyperkalaemiaand clinically 
stable 
(in approved pilot study setting)
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